Kineta, Inc. (KA) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Kineta, Inc.

KA

NASDAQ

Unprofitable

Unprofitable

7M

Biotechnology

Next Earning date - 01 Nov 2024

7M

Biotechnology

Next Earning date - 01 Nov 2024

0.57USD

-0.26 ( -30.77%)

Relative Strenght

2

Volume Buzz

-5%

Earning Acce

No

Dist 52w H.

89%

Quote Panel

Updated October 12, 2024

1W -0.28 % 1M -20.44 % 3M -15.15 % 1Y -83.12 %

Key Metrics

Market Cap
7.05M
Shares Outstanding
12.26M
Share in Float
7.98M
Dividende
0

Earning Date
01 Nov 2024
Price Target
0.5746
Average Volume
504100
Beta
0.5707383

Range
0.3339-5.39
Industry
Biotechnology
Website
https://kinetabio.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

Nanx

P/S Ratio

-0.92x

P/B Ratio

-0.1

Debt/Equity

481.2%

Net Margin

$-1.6

EPS

How KA compares to sector?

P/E Ratio

Relative Strength

KA

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$9M

NaN%

2025-Revenue

$1.35

-575%

2025-EPS

$7M

-185%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-2.17
vs -6.79

Q4.22

N/A

-9.53
vs -6.85

Q1.23

N/A

-0.77
vs -6.16

Q2.23

N/A

-0.08
vs -3.15

Q3.23

N/A

-0.46
vs -2.17

Q4.23

N/A

-0.19
vs -9.53

Q1.24

N/A

-0.89
vs -0.77

Q2.24

N/A

-0.20
vs -0.08

Q3.24

N/A

-0.23
vs -0.46

Q4.24

N/A

-0.24
vs -0.19

Sales Growth

YoY

Current

Estimates

Q3.22

-88%

200K vs 1.6M

Q4.22

-36%

487K vs 762K

Q1.23

-22%

281K vs 358K

Q2.23

+468%

5.2M vs 908K

Q3.23

-100%

NA vs 200K

Q4.23

-991%

-4338000.00 vs 487K

Q1.24

-100%

NA vs 281K

Q2.24

-100%

NA vs 5.2M

Q3.24

NA

300K vs NA

Q4.24

+107%

300K vs -4338000

Return on Equity

QoQ

Q3.22

+26%

0.26
vs 0.31

Q4.22

-1062%

-10.62
vs 0.26

Q1.23

+3896%

38.96
vs -10.62

Q2.23

+5%

0.05
vs 38.96

Q3.23

-198%

-1.98
vs 0.05

Q4.23

-92%

-0.92
vs -1.98

Q1.24

+160%

1.6
vs -0.92

Q2.24

+32%

0.32
vs 1.6

Institutionnal Ownership

Earnings Growth

Latest News

globenewswire.com

6 hours ago

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

globenewswire.com

9 hours ago

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

globenewswire.com

9 hours ago

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

prnewswire.com

9 hours ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

globenewswire.com

16 hours ago

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

globenewswire.com

18 hours ago

Kineta, Inc Transitioning from Nasdaq to OTC Markets

New Feature Coming Soon, Stay Tuned!

Shape

Shape